Why did one of the key people leave Regeneron to come to Rock? Cuz he could and he knows why. Let's not overthink this.
He doesn't have a clue. Looks like it may have been a terrible tragedy is his unwitting way of suggesting he will downplay it. The Putin plan of obfuscation will result in Obama deeming the crash site as unreliable, tampered with and bottom lined inconclusive. Obama is a man of inaction. Well, unless it's fund raising, then he's very proactive.
On our way to the movies a few weeks back, sitting at a red light, here's a panhandler looking for cash. We were running early so we stopped for a quick bite to eat, a nearby Subway. Almost done, the panhandler scoots up to the front door with a nice bike, frame has a built in shock absorber. As he heads to the counter, we see out of his back pocket a cell phone. The freebies that this administration affords, beggars, prostitutes, louts and drug dealers gives them the opportunity to add to their taxpayers' 'gifts' by 'earning' non-taxed income besides. Nice huh?
They raised cash, $9.3 million and a credit option for an additional $5.8 million (subject to certain conditions and limitations), for total available funds of $15.1 million.
Who is willing to deny that the deal demonstrates confidence in this company's viability? IMO it shows that the science involved has value going forward. The very few that are making their exit at such a low share price must be those that have stumbled onto a personal cash crunch.
"A lot of folks have been waiting for the bounce since 5 dollars?"
morgueana666 are there 5 or 500 of them? I don't know and I don't care. Gimme some more stupid.
"Everyone has an agenda?" You converse in a questioning manner. I don't get it.
What is your point in asking "A lot of folks have been waiting for the bounce since 5 dollars?"
Efficacy of drugs can improve by way of synergy; combining drugs is a proven method. He knows.
Dr. Chapman is the Company's President and a member of the Company's Board of Directors. He has served as a member of the Board since September 2005. Since its inception in 1999, Dr. Chapman has served as Chairman and Chief Executive Officer of Chapman Pharmaceutical Consulting, Inc., which provides expert medical consultation on the development and management of domestic and global product development programs for biotech, pharmaceutical, and medical device products. He served as Senior Director of Medical Affairs with Quintiles/BRI, the largest contract research organization in the U.S., from 1995 until 2000. In that capacity, Dr. Chapman had oversight responsibility for the support of new drug applications, clinical studies, and device submissions to the FDA for approval. From 1992 until 1994, Dr. Chapman was Medical Director at Regeneron Pharmaceuticals. He currently serves as Chairman of the Chapman Pharmaceutical Health Foundation. Dr. Chapman is a graduate of the Georgetown University School of Medicine in Washington, D.C.
The problem with your point of view is taking one example, that someone (according to you, a pumper) is telling lies based on the short position. I won't contend that the short position is why someone should own HEB. Nor will I be gullible enough to believe anyone who wilds overstates the short position. At the same time this so-called pumper you refer to, why can't it be someone short HEB who makes an easy to prove statement that is a lie, leaving most readers to believe that those that are long are also liars. You get my point? If not there are longs here that see all the years of R&D as finally nearing significant success. Dec. 2 of last year some excerpts of that days news:
• announced (12/02/13) that it is supporting the University of Pittsburgh's National Institutes of Health funded study (grant 1PO1CA132714) currently underway as part of the University's Chemokine Modulation Research initiative which includes Ampligen® as an adjuvant.
• Dr. Kalinski's group, has successfully completed the lowest tier of dose escalation in patients with resectable (able to reconnect the colon where a portion was removed) colorectal cancer under the clinical leadership of Dr. Amer Zureikat, an assistant professor of surgery. The preliminary results were presented at The Cancer Vaccines and Gene Therapy Meeting, Malvern, PA, October 3-4, 2013
Which moves me to ask, is today's news also pumping as is the above should be seen as pumping? I think you characterize matters that relate to clinical efficacy as pumping.
selling at historic lows is often fear based and misguided by emotion. The sellers allow the buyers to get in low. Maybe you haven't heard, buy low, sell high. It's not about selling low as the way to go. Get it? I can explain it again if you like.
Sentiment: Strong Buy